 Craig Smail
Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multifactorial Inheritance | 5 | 2024 | 17 | 2.190 |
Why?
| | Rare Diseases | 4 | 2024 | 48 | 1.290 |
Why?
| | Phenotype | 2 | 2024 | 257 | 1.080 |
Why?
| | Genetic Predisposition to Disease | 2 | 2024 | 231 | 1.040 |
Why?
| | Sequence Analysis, RNA | 3 | 2024 | 26 | 1.040 |
Why?
| | Genetic Variation | 7 | 2024 | 174 | 0.850 |
Why?
| | Obesity | 1 | 2022 | 125 | 0.750 |
Why?
| | Transcriptome | 4 | 2024 | 59 | 0.650 |
Why?
| | Humans | 18 | 2024 | 6896 | 0.560 |
Why?
| | Genome-Wide Association Study | 4 | 2024 | 190 | 0.500 |
Why?
| | Quantitative Trait Loci | 3 | 2021 | 65 | 0.280 |
Why?
| | Cohort Studies | 2 | 2024 | 289 | 0.260 |
Why?
| | Penetrance | 1 | 2024 | 8 | 0.240 |
Why?
| | Female | 5 | 2024 | 3525 | 0.240 |
Why?
| | Genomics | 2 | 2024 | 101 | 0.240 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2022 | 99 | 0.240 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 18 | 0.240 |
Why?
| | Eosinophilia | 1 | 2024 | 29 | 0.230 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 348 | 0.220 |
Why?
| | Chromatin | 1 | 2023 | 22 | 0.220 |
Why?
| | Trophoblasts | 1 | 2023 | 16 | 0.220 |
Why?
| | Male | 4 | 2024 | 3337 | 0.220 |
Why?
| | Mutation | 2 | 2021 | 212 | 0.220 |
Why?
| | Genome, Human | 2 | 2020 | 86 | 0.210 |
Why?
| | Child | 4 | 2024 | 3364 | 0.210 |
Why?
| | Central Nervous System Stimulants | 1 | 2022 | 11 | 0.200 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2022 | 18 | 0.200 |
Why?
| | Nonsense Mediated mRNA Decay | 1 | 2021 | 1 | 0.200 |
Why?
| | Codon, Nonsense | 1 | 2021 | 6 | 0.200 |
Why?
| | Genetic Diseases, Inborn | 1 | 2021 | 20 | 0.190 |
Why?
| | Population | 1 | 2021 | 2 | 0.190 |
Why?
| | Body Mass Index | 1 | 2022 | 157 | 0.190 |
Why?
| | Disease | 1 | 2021 | 7 | 0.190 |
Why?
| | Primary Health Care | 2 | 2020 | 42 | 0.190 |
Why?
| | RNA, Long Noncoding | 1 | 2021 | 14 | 0.190 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 4 | 0.190 |
Why?
| | RNA, Messenger | 1 | 2021 | 115 | 0.190 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 101 | 0.190 |
Why?
| | Risk Factors | 1 | 2022 | 487 | 0.180 |
Why?
| | Microsatellite Repeats | 1 | 2020 | 7 | 0.180 |
Why?
| | Physicians, Family | 1 | 2020 | 2 | 0.180 |
Why?
| | Herpes Zoster Vaccine | 1 | 2020 | 2 | 0.180 |
Why?
| | Reminder Systems | 1 | 2020 | 5 | 0.180 |
Why?
| | Pneumococcal Vaccines | 1 | 2020 | 4 | 0.180 |
Why?
| | Quality Indicators, Health Care | 1 | 2020 | 17 | 0.180 |
Why?
| | Influenza Vaccines | 1 | 2020 | 28 | 0.170 |
Why?
| | Vaccination | 1 | 2020 | 71 | 0.170 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2019 | 9 | 0.160 |
Why?
| | Pathology, Clinical | 1 | 2018 | 1 | 0.160 |
Why?
| | Laboratory Proficiency Testing | 1 | 2018 | 2 | 0.160 |
Why?
| | Medical Oncology | 1 | 2018 | 18 | 0.160 |
Why?
| | Health Services Misuse | 1 | 2017 | 1 | 0.150 |
Why?
| | Family Practice | 1 | 2018 | 4 | 0.150 |
Why?
| | Community Health Services | 1 | 2018 | 7 | 0.150 |
Why?
| | Patient Participation | 1 | 2018 | 15 | 0.150 |
Why?
| | Immunization | 1 | 2017 | 25 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 55 | 0.150 |
Why?
| | Quality Improvement | 1 | 2017 | 60 | 0.150 |
Why?
| | Cell Line | 3 | 2021 | 81 | 0.130 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 126 | 0.100 |
Why?
| | Organ Specificity | 2 | 2021 | 23 | 0.090 |
Why?
| | Child, Preschool | 2 | 2024 | 1569 | 0.070 |
Why?
| | United States | 2 | 2020 | 669 | 0.070 |
Why?
| | Adult | 2 | 2022 | 1181 | 0.070 |
Why?
| | Enteritis | 1 | 2024 | 4 | 0.060 |
Why?
| | Eosinophilic Esophagitis | 1 | 2024 | 6 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 16 | 0.060 |
Why?
| | Gastritis | 1 | 2024 | 12 | 0.060 |
Why?
| | Colitis, Ulcerative | 1 | 2024 | 13 | 0.060 |
Why?
| | Crohn Disease | 1 | 2024 | 25 | 0.060 |
Why?
| | Biomarkers | 1 | 2024 | 136 | 0.060 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2023 | 14 | 0.060 |
Why?
| | Cell Lineage | 1 | 2023 | 22 | 0.060 |
Why?
| | Placentation | 1 | 2023 | 15 | 0.060 |
Why?
| | Placenta | 1 | 2023 | 21 | 0.060 |
Why?
| | Transcription Factors | 1 | 2023 | 52 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2023 | 59 | 0.060 |
Why?
| | Pregnancy | 1 | 2023 | 216 | 0.050 |
Why?
| | Genome | 1 | 2022 | 32 | 0.050 |
Why?
| | Pedigree | 1 | 2022 | 59 | 0.050 |
Why?
| | Sequence Analysis, DNA | 1 | 2022 | 115 | 0.050 |
Why?
| | Coronary Artery Disease | 1 | 2021 | 10 | 0.050 |
Why?
| | Bardet-Biedl Syndrome | 1 | 2021 | 1 | 0.050 |
Why?
| | Cerebellar Ataxia | 1 | 2021 | 4 | 0.050 |
Why?
| | Calcium Channels | 1 | 2021 | 10 | 0.050 |
Why?
| | Gene Frequency | 1 | 2021 | 90 | 0.050 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2021 | 16 | 0.050 |
Why?
| | Proteins | 1 | 2021 | 27 | 0.050 |
Why?
| | Gene Expression | 1 | 2021 | 67 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2021 | 39 | 0.050 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 41 | 0.050 |
Why?
| | Linkage Disequilibrium | 1 | 2020 | 34 | 0.050 |
Why?
| | Staff Development | 1 | 2020 | 2 | 0.040 |
Why?
| | Task Performance and Analysis | 1 | 2020 | 3 | 0.040 |
Why?
| | Immunization Programs | 1 | 2020 | 6 | 0.040 |
Why?
| | DNA Methylation | 1 | 2021 | 115 | 0.040 |
Why?
| | Program Evaluation | 1 | 2020 | 45 | 0.040 |
Why?
| | Self Report | 1 | 2020 | 42 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2020 | 53 | 0.040 |
Why?
| | Potassium Channels | 1 | 2019 | 1 | 0.040 |
Why?
| | Oxidoreductases Acting on CH-CH Group Donors | 1 | 2019 | 1 | 0.040 |
Why?
| | Acid Ceramidase | 1 | 2019 | 1 | 0.040 |
Why?
| | RNA | 1 | 2019 | 14 | 0.040 |
Why?
| | RNA Splicing | 1 | 2019 | 14 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2021 | 115 | 0.040 |
Why?
| | Models, Genetic | 1 | 2019 | 33 | 0.040 |
Why?
| | Databases, Nucleic Acid | 1 | 2019 | 3 | 0.040 |
Why?
| | Lymphocytes | 1 | 2019 | 15 | 0.040 |
Why?
| | Receptors, Calcitriol | 1 | 2019 | 9 | 0.040 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2019 | 15 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2019 | 215 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2019 | 53 | 0.040 |
Why?
| | Computational Biology | 1 | 2019 | 43 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2019 | 68 | 0.040 |
Why?
| | Middle Aged | 1 | 2020 | 608 | 0.040 |
Why?
| | Algorithms | 1 | 2019 | 105 | 0.040 |
Why?
| | Health Services Research | 1 | 2018 | 4 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2018 | 199 | 0.040 |
Why?
| | Terminology as Topic | 1 | 2017 | 14 | 0.040 |
Why?
| | Adolescent | 1 | 2024 | 2197 | 0.040 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|